Pluristem Therapeutics Inc (PSTI) SEC Filing 8-K Material Event for the period ending Tuesday, May 5, 2020

Pluristem Therapeutics Inc

CIK: 1158780 Ticker: PSTI

View differences made from one to another to evaluate Pluristem Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pluristem Therapeutics Inc.


Assess how Pluristem Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pluristem Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Pluristem Therapeutics Inc provided additional information to their SEC Filing as exhibits

Ticker: PSTI
CIK: 1158780
Form Type: 8-K Corporate News
Accession Number: 0001213900-20-011021
Submitted to the SEC: Tue May 05 2020 4:06:09 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, May 5, 2020
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: